Patients are at the center of everything we do, defining and uniting our efforts for rare diseases, multiple sclerosis, oncology and immunology.
A Leader in Specialty Care
Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, oncology and immunology. We bring hope to people with debilitating and complex genetic conditions that are often difficult to diagnose and treat.
Founded as Genzyme in Boston in 1981, Sanofi Genzyme is one of the world’s leading biotechnology companies, focused on developing highly specialized treatment.
In Pakistan, Sanofi Genzyme started its operations in 2013. We have improved the diagnosis of rare diseases in Pakistan through physician education, awareness programs, support of testing and screening initiatives and provision of cutting-edge free of cost therapies to some patients through global humanitarian programs.
It gives us immense pride to be the company that makes treatments available in Pakistan for Multiple Sclerosis (a disease of the central nervous system) and various genetic conditions, such as, Gaucher, Fabry, MPS I, Pompe diseases, as well as certain thyroid cancers.
Given the rare nature of genetic conditions, there are very few patient support groups/healthcare societies and that too with limited resources. Sanofi Genzyme has forged alliance with physician and patient communities to bring to light numerous issues and challenges encountered by patients, care-givers and families of rare diseases and MS
Raisa was diagnosed with Gaucher disease in 2011. Hailing from Jaranwala, Raisa and her elder brother were both diagnosed with Gaucher at a young age. But unlike her brother whose diagnosis took several years and resulted in the removal of his spleen, Raisa was fortunate enough to get treatment soon after her diagnosis.
Raisa is her father’s darling who is grateful for scientific advancements which has led to the discovery of life-changing treatments that hold promise and hope for patients of rare diseases, especially in a developing country like Pakistan where access to treatment for rare conditions is a major concern.
